Grape King Bio Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	9.4yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Feb 27

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Nov 20

CEO

Grape King Bio has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sheng-Lin Tseng	Chairman & GM	14.8yrs	no data	0.73% NT$ 167.9m
Nick Hung	Accounting Supervisor	10.3yrs	no data	no data
Bing-Jyun Cuei	Chief Legal Officer	2.8yrs	no data	no data

9.4yrs

Average Tenure

Experienced Management: 1707's management team is seasoned and experienced (9.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sheng-Lin Tseng	Chairman & GM	14.8yrs	no data	0.73% NT$ 167.9m
Feng-I Lin	Independent Director	8.8yrs	no data	no data
Chih-Sheng Chang	Director	2.8yrs	no data	2.08% NT$ 476.9m
Mei-Ching Tseng	Director	8.8yrs	no data	1.99% NT$ 456.4m
Jia Chang Jue	Director	14.8yrs	no data	no data
Wei Lai Chih	Director	5.9yrs	no data	0.44% NT$ 100.9m
Shiang Huang Yen	Director	5.9yrs	no data	0.14% NT$ 31.4m
Ching-Pu Chen	Independent Director	8.8yrs	no data	no data
Yifan Miao	Independent Director	5.9yrs	no data	no data
Hsing-Chun Chen	Director	2.8yrs	no data	1.05% NT$ 241.0m
Jing-Ning Chen	Independent Director	2.8yrs	no data	no data
Shiow Ling Kao	Representative Director	2.8yrs	no data	no data

5.9yrs

Average Tenure

Experienced Board: 1707's board of directors are considered experienced (5.9 years average tenure).

Grape King Bio Management

Management criteria checks 2/4

Key information

Recent management updates

Grape King Bio Ltd, Annual General Meeting, May 30, 2024

Less than half of directors are independent

Less than half of directors are independent

Grape King Bio Ltd, Annual General Meeting, May 27, 2022

Grape King Bio Ltd, Annual General Meeting, May 28, 2021

Recent updates

Full year 2023 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 30, 2024

Price target decreased by 12% to NT$170

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Upcoming dividend of NT$6.90 per share at 3.9% yield

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% undervalued after recent price drop

Now 21% undervalued

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of NT$6.10 per share

Grape King Bio Ltd Announces Cash Dividend

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 27, 2022

Grape King Bio Ltd Applies to FDA for A Phase II Clinical Trial Review in Humans for GKAC

Third quarter 2021 earnings released: EPS NT$2.04 (vs NT$2.23 in 3Q 2020)

Price target decreased to NT$195

Second quarter 2021 earnings released: EPS NT$2.20 (vs NT$2.09 in 2Q 2020)

Upcoming dividend of NT$6.40 per share

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

Grape King Bio (TPE:1707) Knows How To Allocate Capital

Here's Why Grape King Bio (TPE:1707) Can Manage Its Debt Responsibly

Grape King Bio's (TPE:1707) Anemic Earnings Might Be Worse Than You Think

Revenue beats expectations

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Full year 2020 earnings released: EPS NT$9.34 (vs NT$9.63 in FY 2019)

Grape King Bio Ltd, Annual General Meeting, May 28, 2021

New 90-day high: NT$181

Grape King Bio Ltd announced that it expects to receive TWD 2.01467 billion in funding from Uni-President Enterprises Corp.

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Price target lowered to NT$206

Third quarter 2020 earnings released: EPS NT$2.23

Earnings beat expectations, revenue disappoints

New 90-day low: NT$167

New 90-day low: NT$176

New 90-day low - NT$178

New 90-day low - NT$184

First half earnings released

CEO

Leadership Team

Average Tenure

Board Members

Average Tenure